Department of Medical Oncology, Faculty of Medicine, Bursa Uludag University, Bursa, Turkey.
Division of Hematology, Department of Internal Medicine, Faculty of Medicine, Bursa Uludag University, Bursa, Turkey.
Bosn J Basic Med Sci. 2021 Dec 1;21(6):746-751. doi: 10.17305/bjbms.2020.5329.
Kaposi sarcoma is a rare disease and there is a gap in the literature about which chemotherapeutics should be applied, especially for the classical type. We aimed to present our institutional data on the demographic characteristics, treatment, and treatment efficacy in 16 Kaposi sarcoma (KS) patients treated with chemotherapy. We retrospectively analyzed the demographic and clinical characteristics, and the chemotherapeutic agents administered to the 16 KS patients diagnosed in our center and treated with chemotherapy, based on the medical records obtained. The median age, gender, type of KS, site of involvement, cytotoxic agents administered, progression-free survival (PFS), overall survival (OS), objective response rate (ORR), disease control rate (DCR), and safety profiles of the patients were evaluated. The median age at disease onset was 61.07 years (range, 39.4-85.8 years). Among the patients, 1 had immunosuppression-related KS, 4 had AIDS-related KS, and 11 had classical KS. In the first-line cytotoxic therapy, 7 patients received pegylated-liposomal doxorubicin (PLD), 6 patients received paclitaxel, 2 patients received oral etoposide, and 1 patient received the adriamycin, bleomycin, and vincristine regimen. In the Kaplan-Meier analysis, the PFS was 39.9 months (95% CI, 7.7-72.0). In the first-line setting, a significant difference in terms of PFS was observed between the PLD- and paclitaxel-treated groups (not reached vs. 12.8 months, p = 0.033). The OS was 66.1 months (95% CI, 30.2-102.0). The ORR of the 16 patients was 43.8%, and their DCR was 81.3%. No grade 3 or 4 toxicity was observed. This retrospective study showed that PLD seems better than paclitaxel in terms of PFS and response rates and it has shown to have a good safety profile in KS patients.
卡波西肉瘤是一种罕见疾病，关于应应用哪种化疗药物存在文献空白，尤其是对于经典型卡波西肉瘤。我们旨在介绍我们机构关于 16 例接受化疗的卡波西肉瘤 (KS) 患者的人口统计学特征、治疗和治疗效果的数据。我们回顾性分析了从病历中获得的 16 例在我们中心诊断并接受化疗的 KS 患者的人口统计学和临床特征，以及所用的化疗药物。评估了患者的中位年龄、性别、KS 类型、受累部位、细胞毒性药物、无进展生存期 (PFS)、总生存期 (OS)、客观缓解率 (ORR)、疾病控制率 (DCR) 和安全性概况。发病时的中位年龄为 61.07 岁(范围为 39.4-85.8 岁)。其中 1 例为免疫抑制相关性 KS，4 例为艾滋病相关性 KS，11 例为经典型 KS。在一线细胞毒性治疗中，7 例患者接受了多柔比星脂质体、6 例患者接受了紫杉醇、2 例患者接受了口服依托泊苷、1 例患者接受了阿霉素、博来霉素和长春新碱方案。在 Kaplan-Meier 分析中，PFS 为 39.9 个月(95%CI，7.7-72.0)。在一线治疗中，PLD 和紫杉醇治疗组之间的 PFS 差异具有统计学意义(未达到 vs. 12.8 个月，p = 0.033)。OS 为 66.1 个月(95%CI，30.2-102.0)。16 例患者的 ORR 为 43.8%，DCR 为 81.3%。未观察到 3 或 4 级毒性。这项回顾性研究表明，PLD 在 PFS 和反应率方面似乎优于紫杉醇，并且在 KS 患者中显示出良好的安全性。
